• Kazuhiro Itoh, Hiroko Shigemi, Keiichi Kinoshita, Hikaru Tsukasaki, Shin Imamura, Koji Morinaga, Nobuyuki Yoshio, Takashi Nakayama, Hitoshi Inoue, Takanori Ueda, Takahiro Yamauchi, and Hiromichi Iwasaki.
• Department of Internal Medicine, National Hospital Organization Awara Hospital, Japan.
• Intern. Med. 2022 Oct 15; 61 (20): 303730443037-3044.

AbstractIntroduction Invasive fungal infections have been attracting attention as significant fatal complications in patients with febrile neutropenia (FN) who undergo intensive chemotherapy or hematopoietic stem cell transplantation to treat hematological malignancies. Although clinical trials are already underway in other countries, evidence supporting the use of caspofungin (CAS) in FN patients in Japan is still insufficient. Methods A retrospective study of patients treated with CAS for FN associated with hematological diseases between April 2015 and March 2018 was conducted to determine the treatment efficacy and safety. The study was conducted as a multicenter collaboration, and the data of 52 patients who met all of the inclusion criteria were analyzed. A five-composite-endpoint method was used, and the treatment was judged to be effective when all five endpoints (defervescence during neutropenia; no breakthrough fungal infections; resolution of baseline fungal infections; a survival for seven days or more after the completion of therapy; and no discontinuation of therapy due to side effects or invalidity) were met. Results The efficacy rate was 53.8% (28/52), which is close to the average reported efficacy rate. Adverse events included liver dysfunction and electrolyte abnormalities, but no renal dysfunction or serious events were seen. Conclusion These results suggest that the use of CAS in FN patients with hematological diseases is effective and well-tolerated, and we believe that the use of CAS could become a significant treatment in Japan.

24 keywords...

hide…